Phase I Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) Alone and in Combination With Docetaxel in Subjects With Advanced Solid Malignancies.

Trial Profile

Phase I Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) Alone and in Combination With Docetaxel in Subjects With Advanced Solid Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Sep 2014

At a glance

  • Drugs 2-deoxy-D-glucose (Primary) ; Docetaxel
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Threshold Pharmaceuticals
  • Most Recent Events

    • 05 May 2009 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
    • 05 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 May 2008 Topline results are expected by the second quarter of 2008 according to a Threshold Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top